CLN — Celon Pharma SA Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Celon Pharma SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.

	2019 December 31st	R2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	PAS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	102	160	199	195	217
Cost of Revenue
Gross Profit	78.9	123	137	128	150
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	95.3	164	210	232	244
Operating Profit	6.9	-3.67	-10.5	-37.3	-27.2
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	7.81	-5.59	-15.1	-36.4	-20
Provision for Income Taxes
Net Income After Taxes	11.9	-0.917	-11.6	-39.3	-28.1
Net Income Before Extraordinary Items
Net Income	11.9	-0.917	-11.6	-39.3	-28.1
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	11.9	-0.917	-11.6	-39.3	-28.1
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.255	-0.027	-0.251	-0.772	-0.565
Dividends per Share